Effects of postmenopausal hormone therapy on rheumatoid arthritis: The women's health initiative randomized controlled trials

Arthritis Care and Research

Volumn 59, Issue 3, 2008, Pages 302-310

  Walitt, Brian ^a   Pettinger, Mary ^b   Weinstein, Arthur ^a   Katz, James ^c   Torner, James ^d   Wasko, Mary Chester ^e   Howard, Barbara V ^f  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f MEDSTAR RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CONJUGATED ESTROGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GOLD DERIVATIVE; HYDROXYCHLOROQUINE; LEFLUNOMIDE; MEDROXYPROGESTERONE; METHOTREXATE; MINOCYCLINE; PENICILLAMINE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HAZARD ASSESSMENT; HAZARD RATIO; HORMONAL THERAPY; HUMAN; INCIDENCE; JOINT SWELLING; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MONOTHERAPY; OUTCOME ASSESSMENT; PAIN ASSESSMENT; POSTMENOPAUSE; PREVALENCE; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SELF REPORT; SHORT FORM 36; STATISTICAL SIGNIFICANCE; WOMEN'S HEALTH;

AGED; ARTHRITIS, RHEUMATOID; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROGESTERONE; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; SEX FACTORS;

EID: 40849134031     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23325     Document Type: Article

References (40)

1. Firestein G. Etiology and pathogenesis of rheumatoid arthritis. In: Kelly's textbook of rheumatology. 6th ed. Richmond (VA): Saunders; 2001. p. 924.
2. Ansar Ahmed S, Penhale WJ, Talal N. Sex hormones, immune responses and autoimmune diseases: mechanisms of sex hormone action. Am J Pathol 1985;121:531-51.
3. Mathur S, Mathur RS, Goust JM, Williamson HO, Fudenberg HH. Cyclic variations in white cell subpopulations in the human menstrual cycle: correlations with progesterone and estradiol. Clin Immunol Immunopathol 1979;13:246-53.
4. Novotny EA, Raveche ES, Sharrow S, Ottinger M, Steinberg AD. Analysis of thymocyte subpopulations following treatment with sex hormones. Clin Immunol Immunopathol 1983;28:205-17.
5. Kramer PR, Kramer SF, Guan G. 17β-estradiol regulates cytokine release through modulation of CD16 expression in monocytes and monocyte-derived macrophages. Arthritis Rheum 2004;50:1967-75.
6. Ansar Ahmed S, Talal N. Sex hormones and autoimmune rheumatic disorders. Scand J Rheumatol 1989;18:69-76.
7. Persellin RH. The effect of pregnancy on rheumatoid arthritis. Bull Rheum Dis 1977;27:922-7.
8. Rudge SR, Kowanko IC, Drury PL. Menstrual cyclicity of finger joint size and grip strength in patients with rheumatoid arthritis. Ann Rheum Dis 1983;42:425-30.
9. Cutolo M, Lahita R. Estrogens and arthritis. Rheum Dis Clin North Am 2005;31:19-27.
10. Wingrave SJ, Kay CR. Reduction in incidence of rheumatoid arthritis associated with oral contraception. Lancet 1978;1:569-71.
11. Vandenbroucke JP, Valkenburg HA, Boersma JW, Cats A, Festen JJ, Huber-Bruning O, et al. Oral contraceptives and rheumatoid arthritis: further evidence for a preventive effect. Lancet 1982;2:839-42.
12. Vandenbroucke JP, Witteman J, Valkenburg H, Boersma JW, Cats A, Festen JJ, et al. Noncontraceptive hormones and rheumatoid arthritis in perimenopausal and postmenopausal women. JAMA 1986;255:1299-303.
13. Linos A, Worthington JW, O'Fallon WM, Kurland LT. Case-control study of rheumatoid arthritis and prior use of oral contraceptives. Lancet 1983;1:1299-300.
14. Carette S, Marcoux S, Gingras S. Postmenopausal hormones and the incidence of rheumatoid arthritis. J Rheumatol 1989;16:911-3.
15. Spector TD, Brennan P, Harris P, Studd JW, Silman AJ. Does estrogen replacement therapy protect against rheumatoid arthritis? J Rheumatol 1991;18:1473-6.
16. Koepsell TD, Dugowson CE, Nelson JL, Voigt LF, Daling JR. Non-contraceptive hormones and the risk of rheumatoid arthritis in menopausal women. Int J Epidemiol 1994;23:1248-55.
17. Doran MF, Crowson CS, O'Fallon WM, Gabriel SE. The effect of oral contraceptives and estrogen replacement therapy on the risk of rheumatoid arthritis: a population based study. J Rheumatol 2004;31:207-13.
18. Hernandez-Avila M, Liang MH, Willet WC, Stampfer MJ, Colditz GA, Rosner B, et al. Exogenous sex hormones and the risk of rheumatoid arthritis. Arthritis Rheum 1990;33:947-53.
19. Merlino LA, Cerhan JR, Criswell LA, Mikuls TR, Saag KG. Estrogen and other female reproductive risk factors are not strongly associated with the development of rheumatoid arthritis in elderly women. Semin Arthritis Rheum 2003;33:72-82.
20. Karlson EW, Mandl LA, Hankinson SE, Grodstein F. Do breast-feeding and other reproductive factors influence future risk of rheumatoid arthritis? Results from the Nurses' Health Study. Arthritis Rheum 2004;50:3458-67.
21. Bijlsma JW, Huber-Bruning O, Thijssen JH. Effect of oestrogen treatment on clinical and laboratory manifestations of rheumatoid arthritis. Ann Rheum Dis 1987;46:777-9.
22. D'Elia HF, Larsen A, Mattsson LA, Waltbrand E, Kvist G, Mellstrom D, et al. Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. J Rheumatol 2003;30:1456-63.
23. Hall GM, Daniels M, Huskisson EC, Spector TD. A randomized controlled trial of the effect of hormone replacement therapy on disease activity in postmenopausal rheumatoid arthritis. Ann Rheum Dis 1994;53:112-6.
24. MacDonald A, Murphy E, Capell H, Bankowska U, Ralston S. Effects of hormone replacement therapy in rheumatoid arthritis: a double blind placebo-controlled study. Ann Rheum Dis 1994;53:54-7.
25. Van den Brink HR, van Everdingen AA, van Wijk MJ, Jacobs JW, Bijlsma JW. Adjuvant oestrogen therapy does not improve disease activity in postmenopausal patients with rheumatoid arthritis. Ann Rheum Dis 1993;52:862-5.
26. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 1998;19:61-109.
27. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al, and the Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
28. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al, and the Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
29. Hays J, Hunt JR, Hubbell FA, Anderson GL, Limacher M, Allen C, et al. The Women's Health Initiative recruitment methods and results. Ann Epidemiol 2003;13(9 Suppl):S18-77.
30. Stefanick ML, Cochrane BB, Hsia J, Barad DH, Liu JH, Johnson SR. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Ann Epidemiol 2003;13(9 Suppl):S78-86.
31. Wiles NJ, Scott DG, Barrett EM, Merry P, Arie E, Gaffney K, et al. Benchmarking: the five year outcome of rheumatoid arthritis assessed using a pain score, the Health Assessment Questionnaire, and the Short Form-36 (SF-36) in a community and a clinic based sample. Ann Rheum Dis 2001;60:956-61.
32. Walitt B, Constantinescu F, Katz J, Weinstein A, Wang H, Khorana RG, et al. Validation of the self-report of rheumatoid arthritis and systemic lupus erythematosus: the Women's Health Initiative. J Rheumatol. In press.
33. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
34. Thomas L. Retrospective power analysis. Conserv Biol 1997;11:276-80.
35. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000;43:1478-87.
36. Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, et al, and the Women's Health Initiative Investigators. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003;348:1839-54.
37. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99.
38. Kvien TK, Glennas A, Knudsrod OG, Smedstad LM, Mowinckel P, Forre O. The prevalence and severity of rheumatoid arthritis in Oslo: results from a county register and population survey. Scand J Rheumatol 1997;26:412-8.
39. Drosos AA, Alamanos I, Voulgari PV, Psychos DN, Katsaraki A, Papadopoulos I, et al. Epidemiology of adult rheumatoid arthritis in northwest Greece 1987-1995. J Rheumatol 1997;24:2129-33.
40. Uhlig T, Kvien TK, Glennas A, Smedstad LM, Forre O. The incidence and severity of rheumatoid arthritis, results from a county register in Oslo, Norway. J Rheumatol 1998;25:1078-84.